Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.52 0.16

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.31

Max

12.59

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+134.87% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-21M 1.1B
Vorige openingsprijs	12.36
Vorige sluitingsprijs	12.52

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 sep 2026, 23:31 UTC

China's Loan Prime Rate announcement on September 21, 2026, is anticipated at 0.03%, amid global tightening trends influenced by rising inflation and Japan's recent rate hike to 1.25%.

19 sep 2026, 23:31 UTC

China's Loan Prime Rate expected to hold at 3.50% on September 21, amid stable market sentiment and focus on international cooperation.

19 sep 2026, 23:11 UTC

U.S. Mortgage Rates Hit 6.97% Amid Fed Rate Hike and Inflation Concerns, Signaling Potential Further Increases Ahead

19 sep 2026, 23:11 UTC

Cautious Market Sentiment Ahead of Chicago Fed National Activity Index Release Amid Disappointing Economic Indicators

19 sep 2026, 23:01 UTC

Avalanche is advancing sharply, continuing its strong upward trend, despite earlier pulling back from a session high, and trading well above its 20-day moving average.

19 sep 2026, 23:01 UTC

Correlated Moves

XRP is advancing, continuing its upward trend since Friday's close, influenced by ongoing geopolitical tensions and recent interest rate hikes by major central banks.

19 sep 2026, 22:51 UTC

Correlated Moves

The Russell 2000 Index is little changed in after-market hours, remaining near the lower end of its one-month range amid ongoing geopolitical tensions.

19 sep 2026, 22:51 UTC

Correlated Moves

Macro News

The Dow Jones Index (US) is trading lower in after-market hours, reflecting minimal movement since Friday's close amid ongoing geopolitical tensions and a new Lockheed Martin contract.

19 sep 2026, 22:51 UTC

The FTSE 100 Index is trading lower in after-market hours, positioned below its 20-day moving average amid ongoing geopolitical tensions affecting energy prices.

19 sep 2026, 22:31 UTC

UK Consumer Confidence Index Forecasted at -16.0 Amid Cautious Market Sentiment and Rising Cost-of-Living Concerns

19 sep 2026, 21:41 UTC

Australia's S&P Global Manufacturing PMI Flash set for September 22, with market expectations at neutral 50 amid cautious optimism and inflation concerns.

19 sep 2026, 21:41 UTC

Australia's S&P Global Services PMI Flash release on September 22 faces cautious optimism amid mixed economic signals and global inflation concerns.

19 sep 2026, 21:21 UTC

Brazil's Central Bank to Release COPOM Meeting Minutes Amid Global Interest Rate Shifts, Influencing Market Sentiment on SELIC Decisions

19 sep 2026, 21:11 UTC

UK CBI Distributive Trades Forecasts -50.0 Amidst Recent Retail Sales Rebound, Indicating Mixed Consumer Sentiment Ahead of Q4

19 sep 2026, 20:41 UTC

UK Manufacturing Sector Faces Caution Ahead of September 2026 CBI Industrial Trends Orders Forecasted at -35.0 Amid Mixed Economic Signals and Rising Cost Pressures.

19 sep 2026, 20:41 UTC

API Crude Oil Stock Change Data Release on September 22, 2026, Amidst Volatile Market Influenced by Geopolitical Tensions and Mixed Investor Sentiment.

19 sep 2026, 19:41 UTC

South Korea's Consumer Confidence Index set for release amid bearish market sentiment and rising interest rates, signaling potential consumer caution.

19 sep 2026, 19:41 UTC

Correlated Moves

EUR/NZD is roughly flat since Friday's close, maintaining stability while the market is closed for the weekend and reflecting its position near the upper end of its one-month range.

19 sep 2026, 19:41 UTC

Macro News

Volkswagen's fiscal outlook revision due to Porsche AG goodwill impairment is contributing to a decline in the IBEX 35 Index amid rising geopolitical tensions.

19 sep 2026, 19:41 UTC

Macro News

The A50 Index (China) is modestly higher in after-market trading, amid rising geopolitical tensions and central bank interest rate hikes affecting risk assets.

19 sep 2026, 19:11 UTC

Germany's Ifo Business Climate Index set for September 24 release amid cautious market sentiment and rising inflation expectations.

19 sep 2026, 18:51 UTC

Investors Brace for Cautious S&P Global Composite PMI Flash Release Amid Rising Inflation Concerns in Euro Area

19 sep 2026, 18:51 UTC

South Africa's Inflation Rate Set for Release Amid Cautious Market Sentiment Following July Decline to 4.3%.

19 sep 2026, 18:51 UTC

Investors Brace for S&P Global Services PMI Flash Release Amid Rising Inflation Concerns and Mixed Economic Signals in Euro Area

19 sep 2026, 18:51 UTC

Euro Area's S&P Global Manufacturing PMI Flash set for September 23, with forecasted growth amid rising inflation concerns and cautious investor sentiment.

19 sep 2026, 18:51 UTC

South Africa's Inflation Rate Release on September 23, 2026 Sparks Caution Among Investors Amid Global Economic Pressures.

19 sep 2026, 18:41 UTC

SNB Expected to Maintain 0% Interest Rate Amid Low Inflation and Strong Franc Ahead of September Decision

19 sep 2026, 18:31 UTC

Spain's Balance of Trade report on September 22, 2026, raises concerns over systemic trade deficits amid rising inflation and cautious market sentiment.

19 sep 2026, 18:21 UTC

Germany's S&P Global Services PMI Flash set for September 23, with cautious market sentiment amid rising inflation expectations and mixed economic indicators.

19 sep 2026, 18:21 UTC

Germany's S&P Global Composite PMI Flash Release on September 23 Expected to Reflect Economic Challenges Amid Inflation and Geopolitical Uncertainty.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

134.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 134.87%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.